Hammeraktie ...und keiner merkts, 358054 - 500 Beiträge pro Seite

[holle72]

Hallo liebe Leute, ich möchte Euch jetzt mal eine sehr, sehr interessante Aktie vorstellen. Ich habe sie selber im Depot und beobachte sie seit langer zeit.
Die schlechten Meldungen aus der Vergangenheit sind längst Geschichte und drei Brokerhäuser beurteilen die Aktie eher positiv. Sie hat den Boden gefunden macht nun immer größerere Schritte nach oben. Sieht sehr interessant aus. Die Spitze im Unternehmen ist ausgetauscht worden und nun bildet Ihr Euch mal eine Meinung. Für mich, der jetzt bei +-0 da steht, ein absoluter Kauf. Strong buy, wenn andere diese Aktie mal bemerken. Bald ist es soweit!!!

Advancis Pharmaceutical 358054 in München handelbar

Advancis Pharmaceutical Appoints R. Gordon Douglas, M.D. Chairman of the Board
E-mail or Print this story

3 February 2006, 07:30am ET

Board of Directors Moves to Separate Chairman and CEO Roles; Douglas Elevated to Chairman and Assumes Role as Chair of Executive Committee;

Dr. Edward M. Rudnic Remains President and Chief Executive Officer and
Member of the Board of Directors
GERMANTOWN, Md., Feb. 3 /PRNewswire-FirstCall/ -- Advancis Pharmaceutical Corporation (Nasdaq: AVNC), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that R. Gordon Douglas, M.D., has been appointed chairman of the board for the Company, effective February 2, 2006. Dr. Douglas has been an Advancis director since 2000, the year the Company began operations. Edward M. Rudnic, Ph.D., co- founder, president, chief executive officer, and former chairman of Advancis, will continue in his role of president and CEO and will remain a member of the Company`s board. Dr. Douglas will also serve as chairman of Advancis` Executive Committee.

"The Advancis board of directors believes elevating Gordon to chairman furthers the spirit of board independence envisioned by the Sarbanes-Oxley Act," said Dr. Edward M. Rudnic, Advancis president and CEO. "Moreover, I believe the breadth of Gordon`s pharmaceutical industry experience and his infectious disease expertise will serve the interests of Advancis stockholders very well. Gordon has been a trusted strategic advisor since I founded the Company, and I look forward to his increased contributions and guidance. Gordon has excelled in all areas of his background including as a medical practitioner, infectious disease professor, and business executive. His reputation as an effective leader and his demonstrated strength of character will be of great benefit as we continue Advancis` development of our proprietary PULSYS product candidates."

"Having been part of the team from the beginning, I appreciate the opportunity and confidence my colleagues at Advancis have demonstrated by appointing me chairman," said Dr. Douglas. "I have great confidence in Ed and the Advancis management team he has assembled, and I will support their efforts to the best of my ability. I look forward to becoming even more involved in charting a path for Advancis` future as I assume the role of chairman."

In addition to his role as Advancis director, Dr. Douglas currently serves as consultant to the Vaccine Research Center at the National Institutes of Health. He was president, Merck Vaccines, responsible for the research, development, manufacturing and marketing of Merck Vaccines` vaccine products, from 1989 until 1999. From 1982 to 1990, he was a professor of medicine and chairman, department of medicine, Cornell University Medical College and physician-in-chief, the New York Hospital. Dr. Douglas also served as head of the infectious disease unit at the University of Rochester School of Medicine.

About Advancis Pharmaceutical Corporation:

Mentioned Last Change
AVNC 1.84 (Unchanged)
Advancis Pharmaceutical Corporation (Nasdaq: AVNC) is a pharmaceutical company focused on the development and commercialization of pulsatile drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently than those under standard treatment regimens. Based on this finding, Advancis has developed a proprietary, once-a-day pulsatile delivery technology called PULSYSTM. By examining the resistance patterns of bacteria and applying its delivery technologies, Advancis has the potential to redefine infectious disease therapy and significantly improve drug efficacy, shorten length of therapy, and reduce drug resistance versus currently available antibacterial products. For more on Advancis, please visit http://www.advancispharm.com .

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on Advancis` current expectations and assumptions. These statements are not guarantees of future performance and are subject to a number of risks and uncertainties that would cause actual results to differ materially from those anticipated. The words, "believe," "expect," "intend," "anticipate," and variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward- looking. Statements in this announcement that are forward-looking include, but are not limited to, statements about the Company`s future development plans, clinical trials, and potential commercial success.

The actual results realized by Advancis could differ materially from these forward-looking statements, depending in particular upon the risks and uncertainties described in the Company`s filings with the Securities and Exchange Commission. These include, without limitation, risks and uncertainties relating to the Company`s financial results and the ability of the Company to (1) reach profitability, (2) prove that the preliminary findings for its product candidates are valid, (3) receive required regulatory approvals, (4) successfully conduct clinical trials in a timely manner with favorable results, (5) establish its competitive position for its products, (6) develop and commercialize products that are superior to existing or newly developed competitor products, (7) develop products without any defects, (8) have sufficient capital resources to fund its operations, (9) protect its intellectual property rights and patents, (10) implement its sales and marketing strategy and reach its sales goals, (11) successfully attract and retain collaborative partners and have its partners fulfill their obligations, and (12) retain its senior management and other personnel. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today`s date. Advancis undertakes no obligation to update or revise the information in this announcement, whether as a result of new information, future events or circumstances or otherwise.

[holle72]

Legt sie Euch auf jeden Fall mal bitte in die watch liste.
Ich war seit langem nicht mehr so überzeugt, kein Gepusche, wird bei dieser Aktie eh nicht funktionieren. Wirklich super. Wer kennt sie schon?

[holle72]

Advancis Pharmaceutical Corporation (NASDAQ: AVNC) 20425 Seneca Meadows Pkwy.
Germantown, MD 20876 (Map)Phone: [phone]
Fax: [phone]
http://www.advancispharm.com

Hoover`s coverage by Danny Cummings

Tools from our advertising partners:
Watch This Company Build A Report Print This Page E-Mail

Overview

Advancis Pharmaceutical Corporation is making advances in the fight against bacteria. The company is developing new and improved formulations of existing antibiotics that are no longer patent protected, using its PULSYS once-a-day delivery technology. Among the antibiotics that the company is researching are amoxicillin, ciprofloxacin, and clarithromycin. Advancis is looking to collaborate with other drugmakers to use its PULSYS technology; the company already has made a deal with GlaxoSmithKline for a formulation of blockbuster antibiotic Augmentin. To cut costs Advancis cut its work force by nearly 40% in mid-2005. HealthCare Ventures owns 37% of Advancis.


Key Numbers

Ranked "Highest in Investor Satisfaction Among Online Trading Services" Company Type Public (NASDAQ: AVNC)
Fiscal Year-End December
2004 Sales (mil.) $11.4
1-Year Sales Growth 216.7%
2004 Net Income (mil.) ($34.0)
2004 Employees 88
1-Year Employee Growth 8.6%

Get more Key Numbers
TIP: Want to stay abreast of the latest in IPO news? Sign up for Hoover`s IPO Update newsletter and start receiving exclusive Hoover`s content delivered straight to your inbox. Each newsletter is delivered weekly to help you stay ahead of the competition.
Key People
Job Openings Chairman, President, and CEO Edward M. Rudnic
(Subscribers see complete biographies -- view sample)
VP, Finance and Acting CFO Robert C. Low
VP, Pharmaceutical Marketing Darren W. Buchwald
Sample more Key People
TIP: Use Build Executive List to target decision makers by industry, geography, sales, net income, and number of employees.
Top Competitors
Johnson & Johnson
Merck
Pfizer
There are 8 competitors for Advancis Pharmaceutical; see more.
TIP: Analyze the Competitive Landscape to view a head-to-head comparison of a firm`s profitability, operations, growth, and valuation versus that of its top three competitors.
Industry Information
Pharmaceuticals
Pharmaceuticals Manufacturers
Drug Delivery Systems (primary)
Generic Drugs
TIP: See what companies are creating the biggest impact each week with Hoover`s Hottest Companies newsletter. Sign up now and start receiving exclusive Hoover`s content delivered straight to your inbox. Each newsletter is delivered weekly to help you stay ahead of the competition. Industry WatchRoundtable Discussion: Pfizer Ruling (5:37)
12/19/05 4:15ET - Lehman Brothers Sr. Pharmaceutical Analyst Tony Butler and Columbia Law School Professor of Corporate & Securities Law John Coffee discuss the Pfizer Lipitor patent lawsuit.
View more industry interviews Keep Informed With Hoover`s Free Newsletters
Sign up now and start receiving exclusive Hoover`s content delivered straight to your inbox. Each newsletter is delivered weekly to help you stay ahead of the competition.

Visit the E-mail Newsletter Preference Center to Subscribe Today!
Trading ToolboxTrading Toolbox
Trade Here Trade Here Trade Here Trade Here
Related Products From Our Trusted PartnersBuy Reports and Books
Drug Delivery Systems: Financial Analysis Profiles

(BizMiner, May 31, 2005, Business Reports)
U.S. Emerging Pulmonary Drug Delivery Technologies Markets

(Frost & Sullivan, Jan 16, 2003, Business Reports)
Generic Drugs and Brand Lifecycle Strategies

(AdvanceTech Monitor, Apr 1, 2002, Business Reports)
Commercial Success in Drug Delivery: An analysis of key technologies and products

(Business Insights, Jun 1, 2003, Business Reports)
Drug Delivery Systems to 2005 (Study # 1454)

(Freedonia Group, Inc., Jul 1, 2001, Business Reports)
Drug Delivery Systems: Marketing Research Profiles

(BizMiner, Dec 15, 2005, Business Reports)
U.S. Emerging Transdermal Drug Delivery Technologies Markets

(Frost & Sullivan, May 9, 2003, Business Reports)
Commercial Success in Drug Delivery: An analysis of key technologies and products

(Business Insights, Jun 1, 2003, Business Reports)
More Reports and Books

Report Search

Additional 3rd Party Libraries

[holle72]

wir liegen schon wieder 4% im Plus. Nicht spektakulär, aber stetig und stets nsch oben mit kleinen Verschnaufpausen.

[holle72]

+6%

[holle72]

gleich knacken wir die 2$ schaut mal bei quote.com
Kürzel avnc and then stream this quote. geht gut ab, schon heute

[holle72]

geknackt, warum schon heute? der kurs wird von den amis gemacht, aber da ist was im busch. jeden tag gehts leicht nach oben bis... die meldung kommt und dann $$$$$$$$

[holle72]

enorm hoher umsatz um die 2$. das ist keine eintagsfliege. Fliegt mit!!!

[holle72]

neuer chef, das ding ist jetzt schon 10%. Weiter gehts

[holle72]

schaut mal den chart an 358054 bei onvista oder so

[holle72]

Advancis Pharmaceutical Corporation is making advances in the fight against bacteria. The company is developing new and improved formulations of existing antibiotics that are no longer patent protected, using its PULSYS once-a-day delivery technology. Among the antibiotics that the company is researching are amoxicillin, ciprofloxacin, and clarithromycin. Advancis is looking to collaborate with other drugmakers to use its PULSYS technology; the company already has made a deal with GlaxoSmithKline for a formulation of blockbuster antibiotic Augmentin. To cut costs Advancis cut its work force by nearly 40% in mid-2005. HealthCare Ventures owns 37% of Advancis.